← Back to Clinical Trials
Recruiting NCT06815887

NCT06815887 Adding Magnesium Sulfate to Local Anesthetic in Combined Pectoral Nerve and Stellate Ganglion Block for Postoperative Pain Control After Modified Radical Mastectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06815887
Status Recruiting
Phase
Sponsor Cairo University
Condition Magnesium Sulfate
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2024-01-15
Primary Completion 2025-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
BupivacaineBupivacaine + Magnesium sulfate

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2024-01-15 with a primary completion date of 2025-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

We aim to study the effect of adding magnesium sulfate as an adjuvant to the local anesthetic used in the combined Pectoralis Nerve Block II (PECS II) and stellate ganglion block for postoperative pain control in patients undergoing modified radical mastectomy.

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years. * Female gender. * American Society of Anesthesiologists (ASA) physical status II or III. * Patients scheduled for elective modified radical mastectomy for breast cancer. * Body mass index (BMI): \> 20 kg/m2 and \< 40 kg/m2. Exclusion Criteria: * Bleeding tendency due to coagulopathy, * Patients with opioid dependence or alcohol or drug abuse, * Significant liver and renal sufficiency * Patients with psychiatric illnesses that prevent them from proper perception and assessment of pain. * Local infection at the site of the block. * Known hypersensitivity or allergy to magnesium sulfate or local anesthetics. * Patients with chronic pain syndromes or pre-existing neuropathic pain conditions. * Pregnant or lactating individuals.

Contact & Investigator

Central Contact

Mahmoud A Ali, Master

✉ dr.ambitious2@gmail.com

📞 00201096799233

Frequently Asked Questions

Who can join the NCT06815887 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Magnesium Sulfate. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06815887 currently recruiting?

Yes, NCT06815887 is actively recruiting participants. Contact the research team at dr.ambitious2@gmail.com for enrollment information.

Where is the NCT06815887 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT06815887 clinical trial?

NCT06815887 is sponsored by Cairo University. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology